SALONPAS
Peakmenthol, methyl salicylate
NDATOPICALPATCH
Approved
Feb 2008
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 7h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SALONPAS is a topical patch containing menthol and methyl salicylate, two counter-irritants that provide localized pain relief through superficial warming and cooling sensations. It is indicated for temporary relief of minor aches and pains of muscles and joints associated with arthritis, backache, strains, and sprains. The product works via topical application to deliver these analgesic agents directly to the affected area without systemic absorption.
Peak3.2 years to LOE
Product is in peak commercial phase with established market presence; team size likely stable but facing imminent generic erosion starting 2027.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.